Search - tctmd.com

Displaying 341 - 360 of 429

Sort: Relevancy | Date

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Leah Lawrence

August 01, 2017

News Daily News

Black Men Have Twofold Higher Risk of Dying From First CHD Event

Michael O'Riordan

July 10, 2017

News Daily News

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

Ashley Lyles

June 20, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

‘Sizeable’ Segment of Public, Even When at High CVD Risk, Feels No Need to Improve Health

Michael O'Riordan

May 04, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Daily News

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

Michael O'Riordan

April 12, 2017

News Daily News

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Yael L. Maxwell

April 11, 2017

News Daily News

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

Alison Palkhivala

April 11, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

Michael O'Riordan

March 08, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Daily News

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Yael L. Maxwell

December 23, 2016

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Shelley Wood

December 02, 2016

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Shelley Wood

September 28, 2016

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

Advertisement

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Black Men Have Twofold Higher Risk of Dying From First CHD Event

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

‘Sizeable’ Segment of Public, Even When at High CVD Risk, Feels No Need to Improve Health

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content